Abstracts tagged "lipids and systemic lupus erythematosus (SLE)"

Abstract Number: 744 • 2018 ACR/ARHP Annual Meeting
Association of PCSK9 Serum Levels with Lipid Metabolism Dysregulation, Activity/Damage Scores and Subclinical Atherosclerosis in SLE Patients
Hiurma Sanchez-Perez¹, Juan Carlos Quevedo², Iñigo Rua-Figueroa³, Beatriz Tejera-Segura⁴, De Vera-González AM⁵, Alejandra Gonzalez-Delgado⁶, Federico Díaz-González⁷ and Iván Ferraz-Amaro⁸, ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, ³Division of Rheumatology, Hospital Doctor Negrín, Las Palmas, Spain, ⁴Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁶Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁷Reumatología, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, ⁸Division of Rheumatology.Hospital Universitario de Canarias, Tenerife, Spain
Background/Purpose: Cardiovascular disease is one of the major causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). SLE patients are characterized by…
Abstract Number: 798 • 2016 ACR/ARHP Annual Meeting
Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus
Subroto Chatterjee¹, Michelle Petri², Steven Jones³ and Vignesh Sadras¹, ¹Pediatrics-Cardiology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Oxidized Phospholipids, Lipoprotein (a) and Glycosphingolipid Associated B- 1,4 Galactosyltransferase in a Johns Hopkins cohort of patients with Systemic Lupus Erythematosus. Background/Purpose: Systemic lupus erythematosus(SLE)…
Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Maureen Sampson², Yenealem Temesgen-Oyelakim³, Alice Fike⁴, Taufiq Salahuddin⁵, Balaji Natarajan⁵, Zerai Manna⁶, Elizabeth Joyal⁶, Marcus Chen⁵, Sarfaraz Hasni⁶, Nehal N. Mehta^5,7, Alan Remaley⁵ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²CC/NIH, Bethesda, MD, ³Office of the Clinical Director,National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵NHLBI, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…
Abstract Number: 848 • 2012 ACR/ARHP Annual Meeting
Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus
Georgia McDonald¹, Laura Miguel¹, Cleo Hall¹, David A. Isenberg², Anthony I. Magee³, Terry Butters⁴ and Elizabeth C. Jury⁵, ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Section of Molecular Medicine, National Heart & Lung Institute, Imperial College London, London, United Kingdom, ⁴Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are characterised by hyperactive T-cells that provide help to auto-reactive B-cells. Underlying this hyperactivity are alterations in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].